Exact Sciences logo

EXAS - Exact Sciences News Story

$104.5 -3.5  -3.2%

Last Trade - 07/05/21

Sector
Healthcare
Size
Large Cap
Market Cap £12.83bn
Enterprise Value £12.67bn
Revenue £1.07bn
Position in Universe 652nd / 6858

BUZZ-Exact Sciences Corp: Truist starts coverage with "buy" rating

Thu 28th January, 2021 1:31pm
** Truist Securities starts coverage of molecular diagnostic
company  EXAS.O  with "buy" rating and PT of $226, implying a
~65% upside to last close
    ** Brokerage believes company set to become a leader
throughout the cancer screening space with its colorectal cancer
detection test Cologuard and strategic acquisitions
    ** Cologuard has already captured 5% of the ~$18 bln
colorectal cancer screening market and is well positioned to
capture 40% - Truist
    ** Brokerage adds recent acquisition of Genomic Health and
Thrive opens up a $3 bln market in breast cancer screening and
$25 bln market in multi-cancer screening
    ** Cancer diagnostics will represent greater than 50% of
sales for the company longer term and allow EXAS to drive
20%-30% top line growth for next 3-5 years - Truist
    ** 14 brokerages rate the stock "buy" or higher, 2 "hold";
Median PT $160 - Refinitiv Eikon
    ** Up to Wednesday's close, shares up ~3.2% this year

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.